Literature DB >> 19748282

Functional implications of genetic variation in human PPARgamma.

Ellen H Jeninga1, Mark Gurnell, Eric Kalkhoven.   

Abstract

The peroxisome proliferator-activated receptor gamma (PPARgamma) plays a key role in the regulation of lipid and glucose metabolism. Human genetic evidence supporting this view comes from the study of both common (e.g. the Pro12Ala polymorphism) and rare (loss-of-function mutations) variants in the gene encoding PPARgamma. Indeed, patients harbouring mutant PPARgamma exhibit familial partial lipodystrophy type 3 and an extreme monogenic form of the metabolic syndrome. The recent elucidation of the crystal structure of the full-length PPARgamma-RXRalpha heterodimer bound to DNA has shed new light on the functional consequences of these genetic PPARgamma alterations and provides novel insights as to why different perturbations of receptor function unite in a common pathway of metabolic dysfunction.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19748282     DOI: 10.1016/j.tem.2009.04.005

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  30 in total

Review 1.  What the genetics of lipodystrophy can teach us about insulin resistance and diabetes.

Authors:  Camille Vatier; Guillaume Bidault; Nolwenn Briand; Anne-Claire Guénantin; Laurence Teyssières; Olivier Lascols; Jacqueline Capeau; Corinne Vigouroux
Journal:  Curr Diab Rep       Date:  2013-12       Impact factor: 4.810

Review 2.  Cytochrome P450-mediated drug metabolism in the brain.

Authors:  Sharon Miksys; Rachel F Tyndale
Journal:  J Psychiatry Neurosci       Date:  2013-05       Impact factor: 6.186

Review 3.  Adipocytes in skin health and disease.

Authors:  Guillermo Rivera-Gonzalez; Brett Shook; Valerie Horsley
Journal:  Cold Spring Harb Perspect Med       Date:  2014-03-01       Impact factor: 6.915

4.  Polymorphisms of peroxisome proliferator-activated receptor γ (PPARγ) and cluster of differentiation 36 (CD36) associated with valproate-induced obesity in epileptic patients.

Authors:  Xupeng Bai; Chuncao Xu; Dingsheng Wen; Yibei Chen; Hongliang Li; Xueding Wang; Liemin Zhou; Min Huang; Jing Jin
Journal:  Psychopharmacology (Berl)       Date:  2018-07-08       Impact factor: 4.530

Review 5.  PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-β/δ and PPAR-γ.

Authors:  Lu Han; Wen-Jun Shen; Stefanie Bittner; Fredric B Kraemer; Salman Azhar
Journal:  Future Cardiol       Date:  2017-06-05

Review 6.  Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease.

Authors:  Salman Azhar
Journal:  Future Cardiol       Date:  2010-09

Review 7.  Defining the molecular nexus of cancer, type 2 diabetes and cardiovascular disease.

Authors:  S M Cabarcas; E M Hurt; W L Farrar
Journal:  Curr Mol Med       Date:  2010-11       Impact factor: 2.222

8.  Genome wide analysis of inbred mouse lines identifies a locus containing Ppar-gamma as contributing to enhanced malaria survival.

Authors:  Selina E R Bopp; Vandana Ramachandran; Kerstin Henson; Angelina Luzader; Merle Lindstrom; Muriel Spooner; Brian M Steffy; Oscar Suzuki; Chris Janse; Andrew P Waters; Yingyao Zhou; Tim Wiltshire; Elizabeth A Winzeler
Journal:  PLoS One       Date:  2010-05-28       Impact factor: 3.240

9.  Is there a biological basis for treatment of fibrodysplasia ossificans progressiva with rosiglitazone? Potential benefits and undesired effects.

Authors:  Renata Bocciardi; Roberto Ravazzolo
Journal:  PPAR Res       Date:  2010-06-16       Impact factor: 4.964

Review 10.  The Role of Adipocytes in Tissue Regeneration and Stem Cell Niches.

Authors:  Brett Shook; Guillermo Rivera Gonzalez; Sarah Ebmeier; Gabriella Grisotti; Rachel Zwick; Valerie Horsley
Journal:  Annu Rev Cell Dev Biol       Date:  2016-05-04       Impact factor: 13.827

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.